natgillin/translations-raw huggingface dataset:
The ex-post audit strategy of the Joint Undertaking was adopted by a Governing Board decision on 14 December 2010 and is a key control for assessing the legality and regularity of the underlying transactions14. 
6 15.Strategija naknadnih revizij Skupnega podjetja IMI, ki jo je s sklepom z dne 14. decembra 2010 sprejel upravni odbor, je ključna kontrola za ocenjevanje zakonitosti in pravilnosti z izkazi povezanih transakcij14.
The ex-post audits that were completed as of September 2012 covered 2,2 million euro (18,8 % of accepted IMI JU contribution for the first call validated by the IMI Joint Undertaking by June 2011). 
V naknadne revizije, ki so bile zaključene do septembra 2012, je bilo zajetih 2,2 milijona EUR (to je 18,8 % sprejetega prispevka Skupnega podjetja IMI za prvi razpis, ki ga je Skupno podjetje IMI potrdilo do junija 2011).
The error rate resulting from these ex-post audits was 6,84 %15. Qualified opinion on the legality and regularity of the transactions underlying the accounts 16.In the Court’s opinion, except for the effects of the matters described in paragraph 15, the transactions underlying the annual accounts of the Joint Undertaking for the year end 31 December 2011, are in all material respects, legal and regular. 
Stopnja napake, ugotovljena med temi naknadnimi revizijami, je bila 6,84 %.15 Mnenje s pridržkom o zakonitosti in pravilnosti z izkazi povezanih transakcij 16.Razen v zvezi z učinki zadeve, opisane v odstavku 15, so po mnenju Sodišča z izkazi povezane transakcije Skupnega podjetja IMI za leto, ki se je končalo 31. decembra 2011, v vseh pomembnih vidikih zakonite in pravilne.
Article 12(4) of Regulation (EC) No 73/2008 setting up the Joint Undertaking states that “The IMI Joint Undertaking shall carry out on-the-spot checks and financial audits among the participants of the Research activities funded by the IMI Joint Undertaking”. 
73/2008 o ustanovitvi Skupnega podjetja je določeno, da „Skupno podjetje IMI izvaja pri udeležencih raziskovalnih dejavnosti, ki jih financira Skupno podjetje IMI, kontrole na kraju samem in finančne revizije“.
Ex_post audits may identify ineligible expenditures claimed by the beneficiaries which are then subject to recovery procedures. 
Pri naknadnih revizijah se lahko ugotovijo neupravičeni odhodki, ki so jih navedli upravičenci in ki se potem izterjajo.
The error rate is calculated using an average of the overdeclarations found in the different cost claims weighted by their amount. 
Stopnja napake se izračuna iz povprečja previsoko navedenih stroškov iz različnih zahtevkov za povračilo stroškov, ki se ponderirajo glede na znesek.
This delayed the launch of the call for proposals. 
Zato je prišlo do zamude pri objavi razpisa za zbiranje predlogov.
During the year, the Joint Undertaking launched the fourth call for proposals, signed five grant agreements for the third call for proposals and eight grant agreements for the second call for proposals. 
Skupno podjetje IMI je med letom objavilo četrti razpis za zbiranje predlogov, podpisalo pet sporazumov o donacijah v okviru tretjega razpisa za zbiranje predlogov in osem sporazumov o donacijah v okviru drugega razpisa za zbiranje predlogov.
19. The implementation rate for the 159 million euro commitment appropriations available for research activities was 66 % and it was implemented through a global commitment covering the fourth call for proposals. 
19.Stopnja izvrševanja odobritev za prevzem obveznosti v višini 159 milijonov EUR, ki so bile na voljo za raziskovalne dejavnosti, je bila 66 %, izvrševanje pa je potekalo v okviru celotne obveznosti, ki pokriva četrti razpis za zbiranje predlogov.
The high level of unused appropriations of the administrative budget (44 %) indicates that it was not based on realistic estimates. 
Visoka stopnja neporabljenih odobritev upravnega proračuna (44 %) kaže na to, da ta ni temeljil na realističnih ocenah.
20. Commitment appropriations amounting to 117 million euro and payment appropriations amounting to 65 million euro not used in the financial year 2010 were carried over to 2011 and commitment appropriations amounting to 62 million euro and payment appropriations amounting to 11 million euro not used during the financial year 2011 were carried over to 2012. 
20.Odobritve za prevzem obveznosti v višini 117 milijonov EUR in odobritve plačil v višini 65 milijonov EUR, ki niso bile porabljene v proračunskem letu 2010, so bile prenesene v leto 2011, odobritve za prevzem obveznosti v višini 62 milijonov EUR in odobritve plačil v višini 11 milijonov EUR, ki niso bile porabljene v proračunskem letu 2011, pa so bile prenesene v leto 2012.
Calls for proposals 21. The calls for proposals organised in 2008, 2009 and 2010 resulted in signed grant agreements amounting to 269 million euro at the end of 2011. 
Razpisi za zbiranje predlogov 21.V okviru razpisov za zbiranje predlogov, ki so bili organizirani v letih 2008, 2009 in 2010, so bili na koncu leta 2011 podpisani sporazumi o donacijah v skupni vrednosti 269 milijonov EUR.
In 2011 the fourth call for proposals was launched with an indicative budgeted EU contribution of 105 million euro. 
Leta 2011 je bil objavljen četrti razpis za zbiranje predlogov, za katerega je bil v proračunu predviden okvirni prispevek EU v višini 105 milijonov EUR.
In 2012 the fifth call for proposals was launched with an indicative budgeted EU contribution of 80 million euro. 
Leta 2012 je bil objavljen peti razpis za zbiranje predlogov, za katerega je bil v proračunu predviden okvirni prispevek EU v višini 80 milijonov EUR.
8 Consequently, if calls for proposals remain at the current level, it is highly likely that the total available EU contribution will not be used. 
Če bodo razpisi za zbiranje predlogov ostali na sedanji ravni, je zato zelo verjetno, da prispevek EU, ki je na voljo, ne bo v celoti porabljen.
Inconsistencies between the Governing Board Decisions and the report on budgetary and financial management 22. 
8 Neskladnosti med sklepi upravnega odbora in poročilom o upravljanju proračuna in finančnem poslovodenju 22.
In the report on budgetary and financial management, the total amount of chapter 30-C2 “Research agenda” (117 million euro) is lower than the budget line B03000-C2 (141 million euro) which is part of the aforementioned chapter. 
V poročilu o upravljanju proračuna in finančnem poslovodenju je skupni znesek v poglavju 30-C2 “raziskovalni program” (117 milijonov EUR) nižji od proračunske vrstice B03000-C2 (141 milijonov EUR), ki je del navedenega poglavja.
In addition, the Governing Board Decision of 28 January 2011 only authorises the carry-over of 115 million euro of commitment appropriations, while the report on budgetary and financial management discloses a carry-over of 117 million euro. 
Poleg tega je bil s sklepom upravnega odbora z dne 28. januarja 2011 odobren samo prenos odobritev za prevzem obveznosti v vrednosti 115 milijonov EUR v naslednje proračunsko leto, v poročilu o upravljanju proračuna in finančnem poslovodenju pa je navedeno, da je bilo prenesenih 117 milijonov EUR.
COMMENTS ON KEY CONTROLS OF THE JOINT UNDERTAKING’S SUPERVISORY AND CONTROL SYSTEMS 23. During 2011 significant progress regarding internal control systems was noted. 
PRIPOMBE O KLJUČNIH KONTROLAH NADZORNEGA IN KONTROLNEGA SISTEMA SKUPNEGA PODJETJA IMI 23.V letu 2011 je bil ugotovljen napredek pri sistemih notranje kontrole.
However, further work is needed to establish and document the budget and accounting procedures and related controls. 
Toda v zvezi z vzpostavitvijo in dokumentiranjem proračunskih in računovodskih postopkov in z njimi povezanih kontrol je potrebno dodatno delo.
In addition, no formal assessment of the internal control system was carried out during 2011. 
Poleg tega v letu 2011 sistem notranje kontrole ni bil formalno ocenjen.
The Accounting Officer reported on the validation of the accounting system on 27 September 2012 and underlined significant weaknesses which need to be addressed17. 
24.Računovodja je 27. septembra 2012 poročal o potrditvi računovodskega sistema in opozoril na pomembne slabosti, ki jih je treba obravnavati17.
17 Major observations reported by the accounting officer: (a) no use of an accurate and established methodology for the calculation of accruals at the end of the financial year (b) improve treasury management and archiving practices (c) formalize the approval of the updated draft manual of financial procedures (d) ensure a complete supporting documentation in payment files (e) introduce an IT-tool in order to better register and manage contracts and agreements. AEI003738EN05-12PP-CH205-12APCFIN-RAS-IMI-OR.DOC 13.11.2012 
Stvarni prispevki se potrjujejo s predhodnim 17 Glavna opažanja, o katerih je poročal računovodja: (a) ne uporablja se natančna in priznana metodologija za izračun vnaprej vračunanih stroškov na koncu proračunskega leta, (b) izboljšati je treba upravljanje zakladnice in prakse arhiviranja, (c) uradno je treba potrditi posodobljeni osnutek priročnika o finančnih postopkih, (d) zagotoviti je treba popolno podporno dokumentacijo v plačilnih dokumentih in (e) uvesti orodje IT za boljše evidentiranje in upravljanje pogodb in sporazumov. AEI003738SL05-12PP-CH205-12APCFIN-RAS-IMI-TR.DOC 13.11.2012
The in-kind contributions are validated by way of an ex-ante certification and ex-post audits. 
9 certificiranjem in naknadnimi revizijami.
In 2011 no ex-ante certification and no ex-post audit were carried out. 
Leta 2011 ni bilo izvedeno nobeno predhodno certificiranje ali naknadna revizija.
OTHER MATTERS Internal audit function and the Commission’s Internal Audit Service 26. 
DRUGE ZADEVE Funkcija notranje revizije in služba Komisije za notranjo revizijo 26.
In 2011 the Commission’s Internal Audit Service and ther Internal Audit Capabilty of the Joint Undertaking carried out a risk assessment exercise and the strategic audit plan for 2012-2014 was approved by the Governing Board on 3 November 2011. 
Služba Komisije za notranjo revizijo in služba za notranjo revizijo v Skupnem podjetju IMI sta leta 2011 opravili oceno tveganja, upravni odbor pa je 3. novembra 2011 odobril strateški revizijski načrt za obdobje 2012–2014.
27. The mission charter of the Commission’s Internal Audit Service was adopted by the Governing Board on 8 March 2011. However, the financial rules of the Joint Undertaking have not yet been amended to include the provision of the Framework Regulation19 . 
27.Listino o delu službe Komisije za notranjo revizijo je upravni odbor sprejel 8. marca 2011, vendar finančna pravila Skupnega podjetja IMI še niso bila spremenjena, tako da bi vsebovala določbe okvirne uredbe19.
28. The Joint Undertaking obtained its autonomy in November 2009, but no internal assurance audit work was performed until March 2012 either by the Internal Audit Service of the Commission or the internal audit manager. 
28.Skupno podjetje IMI je postalo samostojno novembra 2009, vendar do marca 2012 niti služba Komisije za notranjo revizijo niti vodja službe za notranjo revizijo nista opravila nobenega notranjerevizijskega dela za pridobitev zagotovila.
The internal audit manager has been directly involved in operational activities (implementation of ex-post strategy, KPI framework, review of ex-ante certificate on in-kind contributions) and other consultancy engagements. 
Vodja službe za notranjo revizijo je neposredno sodeloval pri operativnih dejavnostih (izvajanje strategije za naknadne revizije, okvira ključnih kazalnikov uspešnosti, pregleda predhodnega certificiranja stvarnih prispevkov) in drugem svetovalnem delu.
18 19 In-kind contributions are the eligible costs incurred by the legal entities participating in the activities which are not reimbursed by the Joint Undertaking. 
18 19 Stvarni prispevki so upravičeni stroški, ki jih imajo pri dejavnostih sodelujoči pravni subjekti in jih Skupno podjetje ne povrne.
Regulation (EC, Euratom) No 2343/2002. 
2343/2002.
AEI003738EN05-12PP-CH205-12APCFIN-RAS-IMI-OR.DOC 13.11.2012 
AEI003738SL05-12PP-CH205-12APCFIN-RAS-IMI-TR.DOC 13.11.2012
Follow up of previous observations 30. A host agreement was concluded on 02 February 2012 between the Joint Undertaking and Belgium concerning the office accommodation, privileges and immunities and other support to be provided by Belgium. 
10 Spremljanje popravnih učinkov prejšnjih ugotovitev 30.Med Skupnim podjetjem IMI in Belgijo je bil 2. februarja 2012 sklenjen sporazum o gostovanju v zvezi z zagotovitvijo pisarn, privilegiji in imunitetami ter drugo podporo, ki jo nudi Belgija.
31. During 2011 the Joint Undertaking made progress on the formalisation of IT security policies. 
31.Skupno podjetje IMI je leta 2011 doseglo napredek pri formalizaciji svojih politik o informacijskotehnološki varnosti.
However, the business continuity plan and disaster recovery plan were not finalised. 
Vendar načrt neprekinjenega poslovanja in obnovitveni načrt po nesreči nista bila dokončana.
Annual activity report 32. According to Article 6.4 of the Statutes of the Joint Undertaking and Article 41 of the IMI Joint Undertaking’s financial rules, the Executive Director is required to draw up an annual activity report including a declaration of assurance stating that the information contained in the report presents a true and fair view except as otherwise specified in any reservation. 
Letno poročilo o dejavnostih 32.V skladu s členom 6.4 Statuta Skupnega podjetja IMI in členom 41 njegovih finančnih pravil mora izvršni direktor pripraviti letno poročilo o dejavnostih, ki vsebuje izjavo o zanesljivosti, v kateri potrdi, da so informacije v poročilu resničen in pošten prikaz stanja, razen če je drugače navedeno v pridržkih.
The declaration of assurance was issued in February 2012 without reservation despite the lack of information on the effectiveness of the ex-post audit strategy, which is the key control for operational expenditure. 
Izjava o zanesljivosti je bila februarja 2012 izdana brez pridržkov, čeprav ni bilo dovolj informacij o uspešnosti strategije naknadnih revizij, ki je ključna kontrola za operativne odhodke.
11 This Report was adopted by Chamber IV, headed by Dr Louis GALEA, Member of the Court of Auditors, in Luxembourg at its meeting of 13 November 2012. 
To poročilo je sprejel senat IV, ki ga vodi dr. Louis GALEA, član Evropskega računskega sodišča, v Luxembourgu na zasedanju 13. novembra 2012.
For the Court of Auditors Vítor Manuel da SILVA CALDEIRA President AEI003738EN05-12PP-CH205-12APCFIN-RAS-IMI-OR.DOC 13.11.2012 
Za Računsko sodišče Vítor Manuel da SILVA CALDEIRA Predsednik AEI003738SL05-12PP-CH205-12APCFIN-RAS-IMI-TR.DOC 13.11.2012
12 Annex Innovative Medicines Initiative Joint Undertaking (Brussels) Competences and activities Areas of Union competence deriving from the Treaty (Extracts from Articles 187 and 188 of the Treaty on the Functioning of the European Union) Competences of the Joint Undertaking Article 187: The Union may set up joint undertakings or any other structure necessary for the efficient execution of Union research, technological development and demonstration programmes. 
11 Priloga Skupno podjetje za pobudo za inovativna zdravila (Bruselj) Pristojnosti in dejavnosti Področja pristojnosti Unije, ki izhajajo iz Pogodbe (odlomka iz členov 187 in 188 Pogodbe o delovanju Evropske unije) Pristojnosti Skupnega podjetja IMI Člen 187: Unija lahko ustanovi skupna podjetja ali kakršno koli drugo strukturo, potrebno za učinkovito izvajanje raziskovalnih, tehnološkorazvojnih in demonstracijskih programov Unije.
Article 188: The Council, on a proposal from the Commission and after consulting the European Parliament and the Economic and Social Committee, shall adopt the provisions referred to in Article 187. 
Člen 188: Svet na predlog Komisije ter po posvetovanju z Evropskim parlamentom in Ekonomsko-socialnim odborom sprejme določbe iz člena 187.
The European Parliament and the Council, acting in accordance with the ordinary legislative procedure and after consulting the Economic and Social Committee, shall adopt the provisions referred to in Articles 183, 184 and 185. 
Evropski parlament in Svet po rednem zakonodajnem postopku in po posvetovanju z Ekonomsko-socialnim odborom sprejmeta določbe iz členov 183, 184 in 185.
Adoption of the supplementary programmes shall require the agreement of the Member States concerned. 
Za sprejetje dopolnilnih programov je potrebno soglasje zadevnih držav članic.
Objectives (Article 2 of Regulation (EC) No 73/2008 setting up the Joint Undertaking) The IMI Joint Undertaking shall contribute to the implementation of the Seventh Framework Programme and in particular the Theme ‘Health’ of the Specific Programme Cooperation implementing the Seventh Framework Programme. 
Cilji (člen 2 Uredbe (ES) št. 73/2008 o ustanovitvi Skupnega podjetja IMI) Skupno podjetje IMI prispeva k izvajanju Sedmega okvirnega programa in zlasti teme „Zdravje“ v sklopu posebnega programa „Sodelovanje“ za izvajanje Sedmega okvirnega programa.
It shall have the objective of significantly improving the efficiency and effectiveness of the drug development process with the long-term aim that the pharmaceutical sector produce more effective and safer innovative medicines. 
Njegov cilj je znatno izboljšati smotrnost in učinkovitost procesa razvoja zdravil; kot dolgoročni cilj pa naj bi farmacevtski sektor proizvedel več učinkovitejših in varnejših inovativnih zdravil.
In particular it shall: (a) support ‘pre-competitive pharmaceutical research and development’ in the Member States and countries associated with the Seventh Framework Programme via a coordinated approach to overcome the identified research bottlenecks in the drug development process; (b) support the implementation of the research priorities as set out by the Research Agenda of the Joint Technology Initiative on Innovative Medicines (hereinafter referred to as ‘Research Activities’), notably by awarding grants following competitive calls for proposals; (c) ensure complementarity with other activities of the Seventh Framework Programme; (d) be a public-private partnership aiming at increasing the research investment in the biopharmaceutical sector in the Members States and countries associated with the Seventh Framework Programme by pooling resources and fostering collaboration between the public and private sectors; (e) promote the involvement of small and medium-sized enterprises (SME) in its activities, in line with the objectives of the Seventh Framework Programme. 
Zlasti: (a) podpira „predkonkurenčne farmacevtske raziskave in razvoj“ v državah članicah in državah, pridruženih k Sedmemu okvirnemu programu, z usklajenim pristopom za odpravljanje ugotovljenih ozkih grl pri raziskavah v procesu razvoja zdravil; (b) podpira izvajanje raziskovalnih prednostnih nalog iz raziskovalnega programa skupne tehnološke pobude za „inovativna zdravila“ (v nadaljnjem besedilu: raziskovalne dejavnosti), predvsem z dodeljevanjem nepovratnih sredstev na podlagi konkurenčnih razpisov za predloge; (c) zagotavlja dopolnjevanje z drugimi dejavnostmi iz Sedmega okvirnega programa; (d) je javno-zasebno partnerstvo, katerega cilj je povečati naložbe v raziskave na biofarmacevtskem področju v državah članicah in državah, pridruženih k Sedmemu okvirnemu programu, z združevanjem virov in spodbujanjem sodelovanja med javnim in zasebnim sektorjem; (e) podpira sodelovanje malih in srednje velikih podjetij (MSP) pri svojih dejavnostih v skladu s cilji Sedmega okvirnega programa.
Tasks (Article 1 of the Annex – Statutes of the Joint Undertaking for the Implementation of the Joint Technology Initiative on Innovative Medicines) The main tasks and activities of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines (hereinafter referred to as IMI Joint Undertaking) shall be the following: (a) to ensure the establishment and sustainable management of the Joint Technology Initiative on ‘Innovative Medicines’; (b) to define and carry out the annual implementation plan referred to in Article 18 via calls for projects; (c) to regularly review and make any necessary adjustments to the Research Agenda of the Joint Technology Initiative on Innovative Medicines in the light of scientific developments occurring during its implementation; (d) to mobilise the public and private sector resources needed; (e) to establish and develop close and long-term cooperation between the Community, industry and the other stakeholders such as regulatory bodies, patients’ organisations, academia and clinical centres, as well as cooperation between industry and academia; AEI003738EN05-12PP-CH205-12APCFIN-RAS-IMI-OR.DOC 13.11.2012 
Naloge (člen 1 Priloge – Statut Skupnega podjetja za izvajanje skupne tehnološke pobude za inovativna zdravila) Glavne naloge in dejavnosti Skupnega podjetja za izvajanje skupne tehnološke pobude za inovativna zdravila (v nadaljnjem besedilu: Skupno podjetje IMI) so: (a) vzpostaviti in trajnostno upravljati skupne tehnološke pobude za „inovativna zdravila“; (b) opredeliti in izvajati letni izvedbeni načrt iz člena 18 z razpisi za prijavo projektov; (c) redno pregledovati in po potrebi prilagajati raziskovalni program skupne tehnološke pobude za „inovativna zdravila“ glede na premike v znanosti v času njegovega izvajanja; (d) mobilizirati potrebne vire iz javnega in zasebnega sektorja; (e) vzpostaviti in razvijati tesno in dolgoročno sodelovanje med Skupnostjo, industrijo in drugimi zainteresiranimi stranmi, kot so regulatorni organi, organizacije bolnikov, akademski krogi in klinični centri, ter sodelovanje med industrijo in akademskimi krogi; (f) pripomoči k lažjemu usklajevanju z nacionalnimi in mednarodnimi dejavnostmi na tem področju; (g) obveščati in razširjati informacije; (h) obveščati države članice in države, ki so pridružene k Sedmemu okvirnemu programu, ter biti v stikih z njimi prek skupine, ustanovljene posebej v ta namen, v nadaljnjem besedilu: skupina predstavnikov držav, vključenih v IMI; AEI003738SL05-12PP-CH205-12APCFIN-RAS-IMI-TR.DOC 13.11.2012